Drugmaker Neurocrine Biosciences said Thursday that the for its tardive dyskinesia drug valbenazine (Ingrezza).
The new product is a single 80-mg capsule that can be taken once a day. Previously, the drug was available only in 40-mg capsules.
"Ingrezza is the only tardive dyskinesia therapy to offer simplified dosing with only one capsule per day," the firm said. The new formulation should be in selected pharmacies within two weeks.